Anti-angiogenic agents for the treatment of brain tumors

Neuroimaging Clinics of North America

Volumn 12, Issue 4, 2002, Pages 477-499

  Fisher, Michael J ^a   Adamson, Peter C ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ME; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOZYME; ANTINEOPLASTIC AGENT; BATIMASTAT; BEVACIZUMAB; CILENGITIDE; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IM 862; INTERLEUKIN 12; LENALIDOMIDE; MARIMASTAT; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY LM 609; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PRINOMASTAT; REBIMASTAT; RECOMBINANT ALPHA INTERFERON; SEMAXANIB; SOLIMASTAT; SQUALAMINE; SURAMIN; TANOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ANEMIA; ANGIOGENESIS; ANIMAL MODEL; ARTHRALGIA; BRAIN TUMOR; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TOLERABILITY; GLIOMA; HUMAN; MENINGIOMA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; MYALGIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA; TUMOR BLOOD FLOW;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; GROWTH SUBSTANCES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036867506     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5149(02)00035-7     Document Type: Review

References (343)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Nat Cancer Inst 1990;82:4-6.
3. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
4. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-24.
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
6. Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol 1998;42:995-1002.
7. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol 2000;50:109-20.
8. Goldbrunner RH, Wagner S, Roosen K, et al. Models for assessment of angiogenesis in gliomas. J Neurooncol 2000;50:53-62.
9. Ferrara N, Houck KA, Jakeman LB, et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211-8.
10. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43.
11. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
12. Cohen T, Gitay-Goren H, Sharon R, et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 1995;270:11322-6.
13. de Vries C, Escobedo JA, Ueno H, et al. The fins-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
14. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-24.
15. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-46.
16. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-86.
17. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946-9.
18. Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995;204:228-39.
19. Plate KH. Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 1999;58:313-20.
20. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
21. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6.
22. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
23. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-8.
24. Webb CP, Vande Woude GF. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000;50:71-87.
25. Kremer C, Breier G, Risau W, et al. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997;57:3852-9.
26. Shen BQ, Lee DY, Gerber HP, et al. Homologous upregulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998;273:29979-85.
27. Pepper MS, Ferrara N, Orci L, et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902-6.
28. Unemori EN, Ferrara N, Bauer EA, et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557-62.
29. Risau W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev 1996;15:149-51.
30. Ikeda E, Achen MG, Breier G, et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761-6.
31. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
32. Stein I, Neeman M, Shweiki D, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995;15:5363-8.
33. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-25.
34. Detmar M, Velasco P, Richard L, et al. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol 2000;156:159-67.
35. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
36. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-37.
37. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78:1379-84.
38. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993;91:153-9.
39. Goldman CK, Bharara S, Palmer CA, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 1997;40:1269-77.
40. Provias J, Claffey K, delAguila L, et al. Meningiomas: Role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997;40:1016-26.
41. Strugar J, Rothbart D, Harrington W, et al. Vascular permeability factor in brain metastases: Correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994;81:560-6.
42. Strugar JG, Criscuolo GR, Rothbart D, et al. Vascular endothelial growth/permeability factor expression in human glioma specimens: Correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995;83:682-9.
43. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24.
44. Heiss JD, Papavassiliou E, Merrill MJ, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996;98:1400-8.
45. Machein MR, Kullmer J, Ronicke V, et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 1999;25:104-12.
46. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
47. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94:8104-9.
48. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
49. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-12.
50. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
51. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 1998;95:8829-34.
52. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
53. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
54. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282:468-71.
55. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
56. Hatva E, Kaipainen A, Mentula P, et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 1995;146:368-78.
57. Kaipainen A, Vlaykova T, Hatva E, et al. Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 1994;54:6571-7.
58. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999;159:391-400.
59. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
60. Kirsch M, Schackert G, Black PM. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol 2000;50:149-63.
61. Koga K, Todaka T, Morioka M, et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001;61:6248-54.
62. Klagsbrun M. The fibroblast growth factor family: Structural and biological properties. Prog Growth Factor Res 1989;1:207-35.
63. Klein S, Roghani M, Rifkin DB. Fibroblast growth factors as angiogenesis factors: New insights into their mechanism of action. EXS 1997;79:159-92.
64. Connolly DT, Stoddard BL, Harakas NK, et al. Human fibroblast-derived growth factor is a mitogen and chemoattractant for endothelial cells. Biochem Biophys Res Commun 1987;144:705-12.
65. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
66. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J Cell Biol 1998;141:1659-73.
67. Pepper MS, Mandriota SJ. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp Cell Res 1998;241:414-25.
68. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995;82:864-73.
69. Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991;113:1193-201.
70. Moscatelli D, Presta M, Rifkin DB. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc Natl Acad Sci USA 1986;83:2091-5.
71. Szabo S, Sandor Z. The diagnostic and prognostic value of tumor angiogenesis. Eur J Surg Suppl 1998;582:99-103.
72. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85:683-93.
73. Varner JA. The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. EXS 1997;79:361-90.
74. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
75. Gladson CL. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 1996;55:1143-9.
76. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
77. Paulus W, Tonn JC. Basement membrane invasion of glioma cells mediated by integrin receptors. J Neurosurg 1994;80:515-9.
78. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
79. Mandriota SJ, Seghezzi G, Vassalli JD, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709-16.
80. Reijneveld JC, Voest EE, Taphoom MJ. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 2000;247:597-608.
81. Chain D, Kreizman T, Shapira H, et al. Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett 1991;285:251-6.
82. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49:117-37.
83. Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 1998;12:135-42.
84. Johnson MD, Kim HR, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194-202.
85. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-33.
86. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75.
87. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ Res 1998;83:832-40.
88. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
89. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997;94:10868-72.
90. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461-7.
91. Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998;95:5579-83.
92. Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000;50:63-70.
93. Ito H, Rovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999;59:5875-7.
94. Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92:4730-41.
95. Stack MS, Gately S, Bafetti LM, et al. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999;340:77-84.
96. Sten-Linder M, Linder C, Strander H, et al. Angiostatin fragments in urine from patients with malignant disease. Anticancer Res 1999;19:3409-14.
97. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
98. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-6.
99. Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000;95:3403-11.
100. Baenziger NL, Brodie GN, Majerus PW. A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci USA 1971;68:240-3.
101. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8.
102. Stiles JD, Ostrow PT, Balos LL, et al. Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 1997;56:435-9.
103. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 1999;96:14888-93.
104. Tolsma SS, Stack MS, Bouck N. Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. Microvasc Res 1997;54:13-26.
105. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504-11.
106. Dawson DW, Bouck NP. Thrombospondin as an inhibitor of angiogenesis. In: Teicher B, editor. Antiangiogenic Agents in Cancer Therapy. Volume 3. Totowana, NJ: Humana Press Inc.; 1999. p. 185-203.
107. DiPietro LA, Nebgen DR, Polverini PJ. Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res 1994;31:178-85.
108. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
109. Hsu SC, Volpert OV, Steck PA, et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996;56:5684-91.
110. Nakagawa T, Kubota T, Kabuto M, et al. Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: Implications for the growth and cellular invasion of the extracellular matrix. J Neurooncol 1996;28:13-24.
111. Nakano A, Tani E, Miyazaki K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995;83:298-307.
112. Rao JS, Steck PA, Mohanam S, et al. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 1993;53:2208-11.
113. Yamamoto M, Sawaya R, Mohanam S, et al. Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. J Neurooncol 1994;22:139-51.
114. Albini A, Melchiori A, Santi L, et al. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991;83:775-9.
115. Anand-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997;38:817-23.
116. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
117. Brooks PC, Silletti S, von Schalscha TL, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
118. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344:82-6.
119. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-65.
120. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993;3:255-68.
121. Wesseling P, van der Laak JA, Link M, et al. Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. Hum Pathol 1998;29:352-8.
122. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11.
123. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72.
124. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
125. Machein MR, Kullmer J, Fiebich BL, et al. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 1999;44:732-41.
126. Nishikawa R, Cheng SY, Nagashima R, et al. Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 1998;96:453-62.
127. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995;55:1189-93.
128. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10-8.
129. Damert A, Machein M, Breier G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 1997;57:3860-4.
130. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 2000;88:2606-18.
131. Murphy PR, Sato R, Sato Y, et al. Fibroblast growth factor messenger ribonucleic acid expression in a human astrocytoma cell line: Regulation by serum and cell density. Mol Endocrinol 1988;2:591-8.
132. Stefanik DF, Rizkalla LR, Soi A, et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 1991;51:5760-5.
133. Brem S, Tsanaclis AM, Gately S, et al. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 1992;70:2673-80.
134. Takahashi JA, Fukumoto M, Igarashi K, et al. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992;76:792-8.
135. Morrison RS, Yamaguchi F, Bruner JM, et al. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 1994;54:2794-9.
136. Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992;52:3213-9.
137. Hermansson M, Nister M, Betsholtz C, et al. Endothelial cell hyperplasia in human glioblastoma: Coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci USA 1988;85:7748-52.
138. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review. Surg Neurol 1998;49:189-96.
139. Plate KH, Breier G, Farrell CL, et al. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 1992;67:529-34.
140. Fernandez-Ruiz E, St-Jacques S, Bellon T, et al. Assignment of the human endoglin gene (END) to 9q34 → qter. Cytogenet Cell Genet 1993;64:204-7.
141. Horst HA, Scheithauer BW, Kelly PJ, et al. Distribution of transforming growth factor-beta 1 in human astrocytomas. Hum Pathol 1992;23:1284-8.
142. Samuels V, Barrett JM, Bockman S, et al. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 1989;134:894-902.
143. Yamada N, Kato M, Yamashita H, et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 1995;62:386-92.
144. Leung SY, Chan AS, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma. Am J Surg Pathol 1997;21:941-50.
145. Hirai R, Kaji K. Transforming growth factor beta 1-specific binding proteins on human vascular endothelial cells. Exp Cell Res 1992;201:119-25.
146. Jennings MT, Maciunas RJ, Carver R, et al. TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: Evidence in support of an autocrine hypothesis. Int J Cancer 1991;49:129-39.
147. Helseth E, Unsgaard G, Dalen A, et al. The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression in a human glioblastoma cell line. J Neurooncol 1988;6:269-76.
148. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett 1996;102:209-15.
149. Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995;147:114-23.
150. Gladson CL, Pijuan-Thompson V, Olman MA, et al. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol 1995;146:1150-60.
151. Abdulrauf SI, Edvardsen K, Ho KL, et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513-20.
152. Kanno H, Kondo K, Ito S, et al. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994;54:4845-7.
153. Krieg M, Marti HH, Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998;92:3388-93.
154. Morii K, Tanaka R, Washiyama K, et al. Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 1993;194:749-55.
155. Weisman AS, Raguet SS, Kelly PA. Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 1987;47:2172-6.
156. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595-9.
157. Christov C, Lechapt-Zalcman E, Adle-Biassette H, et al. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas. Acta Neuropathol (Berl) 1999;98:414-20.
158. Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 1997;93:109-17.
159. Maxwell M, Galanopoulos T, Hedley-Whyte ET, et al. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 1990;46:16-21.
160. Takahashi JA, Mori H, Fukumoto M, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990;87:5710-4.
161. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, et al. Microvessel density in brain tumors. Anticancer Res 1997;17:4747-53.
162. Huber H, Eggert A, Janss AJ, et al. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 2001;37:2064-72.
163. Puduvalli VK, Sawaya R. Antiangiogenesis-therapeutic strategies and clinical implications for brain tumors. J Neurooncol 2000;50:189-200.
164. Hutchinson JW, Tierney GM, Parsons SL, et al. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998;80:907-8.
165. Yu JL, Rak JW, Carmeliet P, et al. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 2001;158:1325-34.
166. Ambs S, Dennis S, Fairman J, et al. Inhibition of tumor growth correlates with the expression level of a human angiostatin transgene in transfected B16F10 melanoma cells. Cancer Res 1999;59:5773-7.
167. Cao Y, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998;101:1055-63.
168. Sim BK, O'Reilly MS, Liang H, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997;57:1329-34.
169. Wu Z, O'Reilly MS, Folkman J, et al. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 1997;236:651-4.
170. Griscelli F, Li H, Bennaceur-Griscelli A, et al. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A 1998;95:6367-72.
171. Kirsch M, Strasser J, Allende R, et al. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 1998;58:4654-9.
172. Sorensen DR, Read TA, Porwol T, et al. Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neuro-oncol 2002;4:1-8.
173. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin. Clin Cancer Res 2001;7:3366-74.
174. Castronovo V, Belotti D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 1996;32A:2520-7.
175. Takamiya Y, Brem H, Ojeifo J, et al. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 1994;34:869-75.
176. Isobe N, Uozumi T, Kurisu K, et al. Antitumor effect of TNP-470 on glial tumors transplanted in rats. Anticancer Res 1996;16:71-6.
177. Taki T, Ohnishi T, Arita N, et al. Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: Potent inhibition of tumor angiogenesis. J Neurooncol 1994;19:251-8.
178. Wilson JT, Penar PL. The effect of AGM-1470 in an improved intracranial 9L gliosarcoma rat model. Neurol Res 1994;16:121-4.
179. Maier JA, Delia D, Thorpe PE, et al. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 1997;8:238-44.
180. Bhargava P, Marshall JL, Rizvi N, et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5:1989-95.
181. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998;16:1444-9.
182. Kudelka AP, Levy T, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997;3:1501-5.
183. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198-203.
184. Moore JD, Dezube BJ, Gill P, et al. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemother Pharmacol 2000;46:173-9.
185. Stadler WM, Kuzel T, Shapiro C, et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17:2541-5.
186. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29:265-73.
187. Gagliardi AR, Kassack M, Kreimeyer A, et al. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 1998;41:117-24.
188. Waltenberger J, Mayr U, Frank H, et al. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 1996;28:1523-9.
189. Coomber BL. Suramin inhibits C6 glioma-induced angiogenesis in vitro. J Cell Biochem 1995;58:199-207.
190. Takano S, Gately S, Engelhard H, et al. Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neurooncol 1994;21:189-201.
191. Bemsen HJ, Rijken PF, Peters JP, et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 1999;44:129-36.
192. Olson JJ, Polk DM, Reisner A. The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma. Neurosurgery 1994;34:297-308.
193. Grossman SA, Phuphanich S, Lesser G, et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol 2001;19:3260-6.
194. Dreicer R, Smith DC, Williams RD, et al. Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 1999;17:183-6.
195. Mirza MR, Jakobsen E, Pfeiffer P, et al. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol 1997;36:171-4.
196. Zamai M, Caiolfa VR, Pines D, et al. Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2- pyrrole]-carbonylimino])bis-(1,3-naphthalene disulfonate). Biophys J 1998;75:672-82.
197. Groen HJ, de Vries EG, Wynendaele W, et al. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: A phase I and pharmacokinetic study. Clin Cancer Res 2001;7:3928-33.
198. Bemsen HJ, Rijken PF, Peters JP, et al. Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurgery 1998;43:570-6.
199. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
200. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996;93:14765-70.
201. Cheng SY, Huang HJ, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996;93:8502-7.
202. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996;56:393-401.
203. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
204. Zhu Z, Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 1999;17:195-212.
205. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-8.
206. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.
207. Shaheen RM, Tseng WW, Vellagas R, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 2001;18:221-6.
208. Arora N, Masood R, Zheng T, et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999;59:183-8.
209. Olson TA, Mohanraj D, Roy S, et al. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 1997;73:865-70.
210. Machein MR, Risau W, Plate KH. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 1999;10:1117-28.
211. Millauer B, Longhi MP, Plate KH, et al. Dominantnegative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996;56:1615-20.
212. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-800.
213. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998;9:823-33.
214. Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998;9:49-58.
215. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-5.
216. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
217. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-6.
218. Rosen L, Mulay M, Mayers A, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. J Clin Oncol 1999;18-161a.
219. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-67.
220. Rak J, Kerbel RS. Prospects and progress in the development of anti-angiogenic agents. Principles and Practice of Biologic Therapy of Cancer 2002;3:1-16.
221. Liekens S, De Clercq E, Neyts J. Angiogenesis: Regulators and clinical applications. Biochem Pharmacol 2001;61:253-70.
222. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000;60:4819-24.
223. Sawaya R, Mandybur T, Ormsby I, et al. Antifibrinolytic therapy of experimentally grown malignant brain tumors. J Neurosurg 1986;64:263-8.
224. Belotti D, Paganoni P, Giavazzi R. MMP inhibitors: Experimental and clinical studies. Int J Biol Markers 1999;14:232-8.
225. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999;878:228-35.
226. Eccles SA, Box GM, Court WJ, et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;56:2815-22.
227. Low JA, Johnson MD, Bone EA, et al. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996;2:1207-14.
228. Santos O, McDermott CD, Daniels RG, et al. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 1997;15:499-508.
229. Sledge Jr. GW, Qulali M, Goulet R, et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995;87:1546-50.
230. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998;4:1899-902.
231. Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999;5:513-20.
232. Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997;23:526-31.
233. Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: A dose-finding study. Am J Clin Oncol 1999;22:247-52.
234. Steward WP. Marimastat (BB2516): Current status of development. Cancer Chemother Pharmacol 1999;43:S56-60.
235. Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16:2150-6.
236. Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001;85:1865-70.
237. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 2001;19:3447-55.
238. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;20:1383-8.
239. Rowinsky EK, Humphrey R, Hammond LA, et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000;18:178-86.
240. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999;878:236-70.
241. Erlichman C, Adjei AA, Alberts SR, et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 2001;12:389-95.
242. Heath EI, O'Reilly S, Humphrey R, et al. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;48:269-74.
243. Hirte H, Goel R, Major P, et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 2000;11:1579-84.
244. D'Olimpio J, Hande K, Collier M, et al. Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. J Clin Oncol 1999;18:160a.
245. Wilding G, Small E, Collier M, et al. A phase I pharmacokinetic evaluation of the matrix metalloproteinase (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancercol. J Clin Oncol 1999;18:323a.
246. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000;5:20-7.
247. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
248. Friedlander DR, Zagzag D, Shiff B, et al. Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Res 1996;56:1939-47.
249. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis. Mol Med 1998;4:741-50.
250. Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000;275:8051-61.
251. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996;8:724-30.
252. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000;6:3056-61.
253. Posey JA, Khazaeli MB, DelGrosso A, et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16:125-32.
254. Lachgar S, Charveron M, Gall Y, et al. Inhibitory effects of retinoids on vascular endothelial growth factor production by cultured human skin keratinocytes. Dermatology 1999;199:25-7.
255. Liaudet-Coopman ED, Berchem GJ, Wellstein A. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin Cancer Res 1997;3:179-84.
256. Kaba SE, Kyritsis AP, Conrad C, et al. The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol 1997;34:145-51.
257. Phuphanich S, Scott C, Fischbach AJ, et al. All-transretinoic acid: A phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol 1997;34:193-200.
258. Yung WK, Kyritsis AP, Gleason MJ, et al. Treatment of recurrent malignant gliomas with high-dose 13-cisretinoic acid. Clin Cancer Res 1996;2:1931-5.
259. Singh RK, Gutman M, Bucana CD, et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
260. Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferonalpha-2b. J Pediatr Hematol Oncol 1997;19:237-44.
261. Jakacki RI, Cohen BH, Jamison C, et al. Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas. J Neurosurg 2000;92:255-60.
262. Mahaley Jr. MS, Urso MB, Whaley RA, et al. Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 1985;63:719-25.
263. Nagai M, Arai T. Clinical effect of interferon in malignant brain tumours. Neurosurg Rev 1984;7:55-64.
264. Buckner JC, Brown LD, Kugler JW, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995;82:430-5.
265. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed highgrade glioma. Cancer 2001;92:420-33.
266. Fine HA, Wen PY, Robertson M, et al. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res 1997;3:381-7.
267. Yung WK, Prados M, Levin VA, et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study. J Clin Oncol 1991;9:1945-9.
268. Packer RJ, Prados M, Phillips P, et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: A childrens cancer group phase I/II study. Cancer 1996;77:2150-6.
269. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
270. Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-43.
271. Moreira AL, Friedlander DR, Shif B, et al. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 1999;43:109-14.
272. Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
273. Patt YZ, Hassan MM, Lozano RD, et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23:319-21.
274. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
275. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-15.
276. Short SC, Traish D, Dowe A, et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 2001;51:41-5.
277. Akhter S, Nath SK, Tse CM, et al. Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. Am J Physiol 1999;276:C136-44.
278. Bhargava P, Marshall JL, Dahut W, et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 2001;7:3912-9.
279. Li D, Williams JI, Pietras RJ. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 2002;21:2805-14.
280. Schiller JH, Bittner G. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: Effects on tumor neovascularization. Clin Cancer Res 1999;5:4287-94.
281. Teicher BA, Williams JI, Takeuchi H, et al. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 1998;18:2567-73.
282. Williams JI, Weitman S, Gonzalez CM, et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res 2001;7:724-33.
283. Kvistad KA, Rydland J, Vainio J, et al. Breast lesions: Evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted firstpass perfusion MR imaging. Radiology 2000;216:545-53.
284. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: Correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-49.
285. Verstraete KL, De Deene Y, Roels H, et al. Benign and malignant musculoskeletal lesions: Dynamic contrast-enhanced MR imaging-parametric "first-pass" images depict tissue vascularization and perfusion. Radiology 1994;192:835-43.
286. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: Dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791-8.
287. Sugahara T, Korogi Y, Tomiguchi S, et al. Post-therapeutic intraaxial brain tumor: The value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901-9.
288. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6.
289. Choyke PL, Knopp MV, Libutti SK. Special techniques for imaging blood flow to tumors. Cancer J 2002;8:109-18.
290. Verstraete KL, Van der Woude HJ, Hogendoom PC, et al. Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: Basic principles and clinical applications. J Magn Reson Imaging 1996;6:311-21.
291. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-50.
292. Tateishi U, Nishihara H, Watanabe S, et al. Tumor angiogenesis and dynamic CT in lung adenocarcinoma: Radiologic-pathologic correlation. J Comput Assist Tomogr 2001;25:23-7.
293. Gradishar WJ. Endpoints for determination of efficacy of antiangiogenic agents in clinical trials. In: Teicher BA, editor. Antiangiogenic Agents in Cancer Therapy. Totowa, NJ: Humana Press Inc.; 1999. p. 341-53.
294. Eckhardt SG, Pluda JM. Development of angiogenesis inhibitors for cancer therapy. Invest New Drugs 1997;15:1-3.
295. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-55.
296. Kerbel RS, Viloria-Petit A, Klement G, et al. 'Accidental' anti-angiogenic drugsanti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000;36:1248-57.
297. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
298. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
299. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
300. Sasaki M, Wizigmann-Voos S, Risau W, et al. Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Int J Dev Neurosci 1999;17:579-91.
301. Nguyen JT, Wu P, Clouse ME, et al. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 1998;58:5673-7.
302. Tanaka T, Cao Y, Folkman J, et al. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998;58:3362-9.
303. Ma HI, Guo P, Li J, et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res 2002;62:756-63.
304. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997;3:437-42.
305. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:2002-7.
306. Yokoyama Y, Dhanabal M, Griffioen AW, et al. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-6.
307. Teicher BA, Holden SA, Ara G, et al. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 1996;38:169-77.
308. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-91.
309. Tu SM, Pagliaro LC, Banks ME, et al. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res 1998;4:1193-201.
310. Johnson DH, DeVore R, Kabbinvar R, et al. Carboplatin (C) + paclitaxel (T) - RhuMAb-VEGF (AVF) may prolong survival in advanced non-squamous lung cacner. Proc Am Soc Clin Oncol 2001;0:315a.
311. AstraZeneca International. Available at: Http://www. astazeneca.com/mainnav1/s_research/s_research_therapy/s_research_oncology/c_ research_therapy/oncology.asp. Accessed 2002.
312. EntreMed. Available at: Http://www.entremed.com/patient/alltrials.cfm. Accessed 2002.
313. National Cancer Institute. Angiogenesis Inhibitors in Clinical Trials. Available at: Http://www.cancer. gov/clinical_trials/doc.aspx?viewid=B0959CBB-3004-4160-A679-6DD204BEE68C. Accessed 2002.
314. National Cancer Institute. Clinical Trials (PDQ®). Available at: Http://www.cancer.gov/search/clinical_ trials/results_clinicaltrials.aspx. Accessed 2002.
315. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997;94:861-6.
316. Brem S. Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Available at: Http://www.moffitt.usf.edu/pubs/ccj/v6n5/article2.htm. Accessed 1999.
317. Dameron KM, Volpert OV, Tainsky MA, et al. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994;59:483-9.
318. Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 1999;30:419-24.
319. Grugel S, Finkenzeller G, Weindel K, et al. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-9.
320. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
321. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161-5.
322. Raffel C, Frederick L, O'Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999;5:4085-90.
323. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor anglogenesis. Cancer Res 1995;55:4575-80.
324. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34-44.
325. Royds JA, Dower SK, Qwamstrom EE, et al. Response of tumour cells to hypoxia: Role of p53 and NFkB. Mol Pathol 1998;51:55-61.
326. Siemeister G, Weindel K, Mohrs K, et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56:2299-301.
327. Takahashi Y, Bucana CD, Cleary KR, et al. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998;79:34-8.
328. Theurillat JP, Hainfellner J, Maddalena A, et al. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am J Pathol 1999;154:581-90.
329. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998;58:2288-92.
330. Kaelin WG, Iliopoulos O, Lonergan KM, et al. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 1998;243:535-9.
331. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-95.
332. Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996;122:3829-37.
333. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96:2811-6.
334. Taddei L, Chiarugi P, Brogelli L, et al. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun 1999;263:340-5.
335. Yazaki T, Takamiya Y, Costello PC, et al. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol 1995;23:23-9.
336. Wizigmann-Voos S, Breier G, Risau W, et al. Upregulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995;55:1358-64.
337. Heyns AD, Eldor A, Vlodavsky I, et al. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res 1985;161:297-306.
338. Thompson WD, Stirk CM, Melvin WT, et al. Plasmin, fibrin degradation and angiogenesis. Nat Med 1996;2:493.
339. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
340. Landau BJ, Kwaan HC, Verrusio EN, et al. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 1994;54:1105-8.
341. Raithatha SA, Muzik H, Rewcastle NB, et al. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro-oncol 2000;2:145-50.
342. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994;54:5016-20.
343. Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999;19:959-68.